In vitro evolution of the human immunodeficiency virus type 1 Gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure

被引：12

作者：

Catamancio, SL ^{[1
]}

De Pasquale, MP ^{[1
]}

Citterio, P ^{[1
]}

Kurtagic, S ^{[1
]}

Galli, M ^{[1
]}

Rusconi, S ^{[1
]}

机构：

[1] Univ Milan, Osped Luigi Sacco, Inst Malattie Infettive, I-20157 Milan, Italy

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2001年 / 39卷 / 03期

关键词：

D O I：

10.1128/JCM.39.3.1124-1129.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We studied the human immunodeficiency virus type 1 phenotypic and genotypic profiles of a dual drug-resistant isolate (isolate 14aPost-DR) selected for zidovudine (ZDV) and lamivudine (3TC) resistance and then cultured in the presence of 3TC and a protease inhibitor: indinavir (IDV), ritonavir, or KNI-272. The IDV-treated virus was highly resistant to 3TC, ZDV, and IDV and accumulated protease mutations at positions M46I and V82F. A change from alanine to valine was observed in 4 of 10 clones in the P2 position of the p7-p1 Gag-protease cleavage site, linked to position M46I in the dominant viral quasispecies. Previous 3TC resistance did not impair the development of additional mutations in the protease and Gag-protease cleavage regions.

引用

页码：1124 / 1129

页数：6

共 30 条

[1] [Anonymous], 1995, Phylogeny inference package (PHYLIP)
[2] HIV-1 drug resistance in newly infected individuals
Boden, D
Hurley, A
Zhang, LQ
Cao, YZ
Guo, Y
Jones, E
Tsay, J
Ip, J
Farthing, C
Limoli, K
Parkin, N
Markowitz, M
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12): : 1135 - 1141
[3] Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug
Borman, AM
Paulous, S
Clavel, F
[J]. JOURNAL OF GENERAL VIROLOGY, 1996, 77 : 419 - 426
[4] Virological and clinical implications of resistance to HIV-I protease inhibitors
Condra, JH
[J]. DRUG RESISTANCE UPDATES, 1998, 1 (05) : 292 - 299
[5] Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
Condra, JH
Holder, DJ
Schleif, WA
Blahy, OM
Danovich, RM
Gabryelski, LJ
Graham, DJ
Laird, D
Quintero, JC
Rhodes, A
Robbins, HL
Roth, E
Shivaprakash, M
Yang, T
Chodakewitz, JA
Deutsch, PJ
Leavitt, RY
Massari, FE
Mellors, JW
Squires, KE
Steigbigel, RT
Teppler, H
Emini, EA
[J]. JOURNAL OF VIROLOGY, 1996, 70 (12) : 8270 - 8276
[6] IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS
CONDRA, JH
SCHLEIF, WA
BLAHY, OM
GABRYELSKI, LJ
GRAHAM, DJ
QUINTERO, JC
RHODES, A
ROBBINS, HL
ROTH, E
SHIVAPRAKASH, M
TITUS, D
YANG, T
TEPPLER, H
SQUIRES, KE
DEUTSCH, PJ
EMINI, EA
[J]. NATURE, 1995, 374 (6522) : 569 - 571
[7] THE HIV-1 PROTEASE AS A THERAPEUTIC TARGET FOR AIDS
DEBOUCK, C
[J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) : 153 - 164
[8] HIV-1 protease inhibitors - A review for clinicians
Deeks, SG
Smith, M
Holodniy, M
Kahn, JO
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02): : 145 - 153
[9] Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
Doyon, L
Croteau, G
Thibeault, D
Poulin, F
Pilote, L
Lamarre, D
[J]. JOURNAL OF VIROLOGY, 1996, 70 (06) : 3763 - 3769
[10] DULBECCO R, 1988, VIROLOGY M, V69, P23

← 1 2 3 →